Gilead Sciences Inc (GILD) Stock Analysis

Gilead Sciences Inc (GILD) is a publicly traded company in the HEALTHCARE sector. It trades at $127.57, carries a market capitalization of $162.77B, a price-to-earnings ratio of 17.84, a dividend yield of 0.02%. This page summarizes the public market data, fundamentals, and frequently asked questions for GILD, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - GENERAL

Exchange: NASDAQ

Key Metrics

Market Sentiment

Gilead Sciences Inc currently has a Bullish sentiment score of 0.19.

About Gilead Sciences Inc

Gilead Sciences, Inc. is a prominent biopharmaceutical company headquartered in Foster City, California, specializing in the research, development, and commercialization of innovative antiviral therapies targeting infectious diseases, including HIV and hepatitis. Its flagship products, such as Harvoni and Sovaldi, have significantly advanced treatment protocols for chronic hepatitis C, highlighting Gilead's leadership in the field. Emphasizing its commitment to addressing unmet medical needs,...

GNG Research Analysis

GNG Research scores Gilead Sciences Inc (GILD) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GILD.

Frequently Asked Questions

What is GILD's current dividend yield?

Gilead Sciences Inc (GILD) has a current dividend yield of 0.02%.

Does GILD pay dividends?

Yes, Gilead Sciences Inc pays dividends with a current yield of 0.02%.

What is GILD's P/E ratio?

Gilead Sciences Inc has a price-to-earnings (P/E) ratio of 17.84.

What is GILD's market cap?

Gilead Sciences Inc (GILD) has a market capitalization of $162.77B with a current stock price of $127.57.